Publications

2026

• PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.

  Ge X, Singh J, Li W, Markham CS, Ruiz CF, Stites EC, Bhattacharyya M, Liu Y, Muzumdar MD. PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer Res 2026 PMID: 42095550, DOI: 10.1158/0008-5472.CAN-25-3625.

  Peer-Reviewed Original Research

  This study investigates how PI3K enables pancreatic cancer cells to resist KRAS inhibitors by activating wild-type RAS signaling, suggesting combined PI3K-KRAS targeting as a therapeutic strategy.

  Full Summary

• HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results

  Braun DA, Noel MS, Moy RH, Demel K, Gutierrez M, Sharma S, Hussain A, Gadgeel S, Peguero J, Choueiri TK, Emamekhoo H, Van Tine B, Balaraman R, Elliott G, Nath S, Daigle SR, Kumar P, Scheuber A, Sommerhalder D. HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. Cell Reports Medicine 2026, 102789. DOI: 10.1016/j.xcrm.2026.102789.

  Peer-Reviewed Original Research

• Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas.

  Ruiz CF, Ge X, McDonnell R, Agabiti SS, McQuaid DC, Tang A, Kharwa M, Goodell J, Saavedra-Pena RDM, Wing A, Li G, Medici NP, Robert ME, Varshney RR, Rudolph MC, Gorelick FS, Wysolmerski J, Canals D, Haley JD, Rodeheffer MS, Muzumdar MD. Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. Cancer Discov 2026 PMID: 42053430, DOI: 10.1158/2159-8290.CD-25-0734.

  Peer-Reviewed Original Research

  This study investigates how dietary fat composition influences pancreatic cancer, showing that monounsaturated fats promote tumor growth while polyunsaturated fats reduce risk by enhancing ferroptosis sensitivity.

  Full Summary

• Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab.

  Savion-Gaiger N, Perales O, Su DG, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open 2026, 11: 106908. PMID: 42013628, DOI: 10.1016/j.esmoop.2026.106908.

  Peer-Reviewed Original Research

  This study investigates biomarkers in renal cell carcinoma, showing tumor PD-L1 expression predicts better survival with immunotherapy, while neutrophil markers highlight sarcomatoid/rhabdoid tumor immune environments.

  Full Summary

• BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.

  Harding JJ, Hofheinz R, Élez E, Kuboki Y, Rasco DW, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Haderk F, Mészáros L, Wölke S, Katakabe T, Lorence RM, Van Cutsem E, Kopetz S, Pant S. BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. Cancer Res Commun 2026 PMID: 41987415, DOI: 10.1158/2767-9764.CRC-25-0638.

  Peer-Reviewed Original Research

• Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry

  Pine A, Butt A, Andreoli L, Knight J, Gerosa M, Cecchi I, Branch D, Lopez-Pedrera R, Belmont H, Kello N, Petri M, Cervera R, Pengo V, Meroni P, Cohen H, Willis R, Bertolaccini M, Goshua G, Gu S, Hwa J, Lee A, Erkan D, Sharda A. Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry. Frontiers In Immunology 2026, 17: 1807468. DOI: 10.3389/fimmu.2026.1807468.

  Peer-Reviewed Original Research

  Concepts

• Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  Mohty R, Narra R, Mims A, Hunter C, Shallis R, Kota V, Jamy O, Coltoff A, Othman T, Jonas B, Patel A, DuVall A, Foucar C, Abdelsamia M, Palmisiano N, Patel S, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2026, ahead-of-print: 1-8. PMID: 41954351, DOI: 10.1080/10428194.2026.2650679.

  Peer-Reviewed Original Research

  This study investigates predictors of complete molecular response (CMR) and shows that early CMR improves relapse-free survival in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

  Full Summary

• Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer

  Mihailescu M, Fish A, Madoff D. Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer. Cancers 2026, 18: 1189. DOI: 10.3390/cancers18081189.

  Peer-Reviewed Original Research

  This study investigates advances in minimally invasive therapies for lung cancer, showing improved tumor targeting, safety, and potential benefits when combined with immunotherapy and chemotherapy.

  Full Summary

• In Reply to: “Response to Intra-arterial Chemotherapy in Patients with Adenoid Cystic Carcinoma of Lacrimal Gland”

  Costa P, Tse D, Benedetto P. In Reply to: “Response to Intra-arterial Chemotherapy in Patients with Adenoid Cystic Carcinoma of Lacrimal Gland”. The Oncologist 2026, oyag087. PMID: 41955416, DOI: 10.1093/oncolo/oyag087.

  Peer-Reviewed Original Research

  Concepts

• ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.

  Stockhammer P, El Zarif T, Schillo JL, Li F, Goldberg SB, Politi K, Grant MJ. ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. J Thorac Oncol 2026, 103708. PMID: 41932614, DOI: 10.1016/j.jtho.2026.103708.

  Peer-Reviewed Original Research

• 441TiP SEZanne: A phase II randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC)

  Cuppens K, Goto Y, Byers L, Ardizzoni A, Paz-Ares L, Zhou C, Dowlati A, Cooper A, Bar J, Lee S, Jahchan N, Zhao Y, Meiman D, Fang F, Rivell G, Palenski T, Chiang A. 441TiP SEZanne: A phase II randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC). ESMO Open 2026, 11: 106755. DOI: 10.1016/j.esmoop.2026.106755.

  Peer-Reviewed Original Research

  This study investigates PF-08634404, a dual-action antibody targeting PD-1 and VEGF, combined with chemotherapy for extensive-stage small cell lung cancer to improve survival outcomes.

  Full Summary

• 442TiP DeLLphi-312 phase III trial-in-progress: Tarlatamab with durvalumab, carboplatin and etoposide versus durvalumab, carboplatin and etoposide as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC)

  Korantzis I, Lu S, Itchins M, Majem M, Akamatsu H, Loong H, Goldman J, Chiang A, Baka S, Mazieres J, Hamidi A, Shaw C, de la Guardia D, Bluthgen M, Reck M. 442TiP DeLLphi-312 phase III trial-in-progress: Tarlatamab with durvalumab, carboplatin and etoposide versus durvalumab, carboplatin and etoposide as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC). ESMO Open 2026, 11: 106756. DOI: 10.1016/j.esmoop.2026.106756.

  Peer-Reviewed Original Research

  Concepts

• LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

  Besse B, Felip E, Cho B, Takahashi T, Politi K, Wang J, De Castro G, Kowalczyk-Tekiela A, Bonanno L, Muntean A, Russo G, Pradera J, Kim S, Florescu M, Chen P, Pons-Tostivint E, Chepka Y, Mann H, Rogerio J, Forde P. LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY. ESMO Open 2026, 11: 106957. DOI: 10.1016/j.esmoop.2026.106957.

  Peer-Reviewed Original Research

  Concepts

• 423P IMforte: Subsequent treatment (Tx) following first-line maintenance (1Lm) with lurbinectedin (lurbi) + atezolizumab (atezo) or atezo in extensive stage small cell lung cancer (ES-SCLC)

  Chen Y, Paz-Ares L, Borghaei H, Reck M, Herbst R, Peters S, Czyzewicz G, Bernabe R, Johnson M, Karadurmus N, Grohe C, Baka S, Csoszi T, Wang X, Bhatt K, Faderl S, Graupner V, Cuchelkar V, Lin Y, Liu S. 423P IMforte: Subsequent treatment (Tx) following first-line maintenance (1Lm) with lurbinectedin (lurbi) + atezolizumab (atezo) or atezo in extensive stage small cell lung cancer (ES-SCLC). ESMO Open 2026, 11: 106737. DOI: 10.1016/j.esmoop.2026.106737.

  Peer-Reviewed Original Research

  Concepts

• dpGMM: A new R package for efficient and robust Gaussian mixture modeling of 1D and 2D data

  Zyla J, Szumala K, Polanski A, Polanska J, Marczyk M. dpGMM: A new R package for efficient and robust Gaussian mixture modeling of 1D and 2D data. Journal Of Computational Science 2026, 95: 102811. DOI: 10.1016/j.jocs.2026.102811.

  Peer-Reviewed Original Research

  Citations

  Concepts

• 58P Real-world intracranial effectiveness of sotorasib in second-line (2L) and beyond (2L+) treatment (tx) of KRAS G12C-mutated non-small cell lung cancer (NSCLC) with brain metastases (BM)

  Nadal E, Sabari J, Dingemans A, Gadgeel S, Lee J, Wolf J, Ko H, Gupta R, Jassim R, Ardito-Abraham C, Frias M, Goldberg S. 58P Real-world intracranial effectiveness of sotorasib in second-line (2L) and beyond (2L+) treatment (tx) of KRAS G12C-mutated non-small cell lung cancer (NSCLC) with brain metastases (BM). ESMO Open 2026, 11: 106365. DOI: 10.1016/j.esmoop.2026.106365.

  Peer-Reviewed Original Research

  This study investigates sotorasib's real-world effectiveness in KRAS G12C-mutated lung cancer with brain metastases, showing intracranial activity and survival outcomes consistent with clinical trials.

  Full Summary

• 42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

  Sands J, Lisberg A, Le X, Shum E, Hendriks L, Yu H, Riess J, Goto Y, Piotrowska Z, Tang K, Harper J, Pölsterl S, Failmezger H, Vonficht D, Chiaverelli R, Lehman J, Fraenkel P, Zebger-Gong H, Goldberg S, Ahn M. 42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC. ESMO Open 2026, 11: 106349. DOI: 10.1016/j.esmoop.2026.106349.

  Peer-Reviewed Original Research

  Concepts

• 306P Real-world outcomes and determinants of immune-mediated pneumonitis in stage III NSCLC treated with durvalumab after chemoradiotherapy

  Lorca A, Vilalta A, Ferrandez J, Muñoz M, Ortego M, Sunyer A, Alencastre A, Pangua-Irigaray P, Arango N, Gurpide A, Moreno M, Sanmamed M, Unanua N. 306P Real-world outcomes and determinants of immune-mediated pneumonitis in stage III NSCLC treated with durvalumab after chemoradiotherapy. ESMO Open 2026, 11: 106616. DOI: 10.1016/j.esmoop.2026.106616.

  Peer-Reviewed Original Research

  Concepts

• 1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation

  Paz-Ares L, Spira A, Hollebecque A, Cassier P, Fountzilas C, Jung M, Kim S, Morgensztern D, Nishina T, Lovly C, Lorusso P, Italiano A, You B, Mercade T, Hayashi H, Gill S, Lee H, Kadam S, Shetty A, Goldman J. 1O Efficacy and safety of setidegrasib in patients (pts) with advanced NSCLC with KRAS G12D mutation. ESMO Open 2026, 11: 106308. DOI: 10.1016/j.esmoop.2026.106308.

  Peer-Reviewed Original Research

• Hepatic Augmentation

  Tefera J, Madoff D. Hepatic Augmentation. 2026, 505-526. DOI: 10.1007/978-3-032-03935-4_33.

  Peer-Reviewed Original Research

  Concepts

• Malignant Hematological Diseases: Hyperleukocytosis

  Gowda L, Hosing C. Malignant Hematological Diseases: Hyperleukocytosis. 2026, 1-10. DOI: 10.1007/978-3-319-74698-2_94-2.

  Peer-Reviewed Original Research

  Concepts

• FUNCellA: a tool for single-sample enrichment analysis and relative pathway activity estimation in single-cell RNA sequencing data

  Zyla J, Mrukwa A, Bilska A, Szumala K, Polanska J, Marczyk M. FUNCellA: a tool for single-sample enrichment analysis and relative pathway activity estimation in single-cell RNA sequencing data. Computational And Structural Biotechnology Journal 2026 DOI: 10.34133/csbj.0053.

  Peer-Reviewed Original Research

  Concepts

• The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets.

  Lee J, Quintanilha J, Chen K, Fendler B, Tambaoan C, Graf R, Odzer N, Pusztai L, Lustberg M, Singh H, Strickland M, O'Meara T, Tolaney S, Yap T, Ross J, Gasco Hernandez A, Decker B, Huang R, Klempner S, Sokol E, Schrock A. The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets. Clinical Cancer Research 2026 PMID: 41870274, DOI: 10.1158/1078-0432.ccr-25-4018.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Liquid plasma versus thawed plasma: Tracking coagulation factor activity changes during storage

  Yurtsever N, Gereg C, Perera N, Bahel P, Alicea M, Rinder H, Snyder E, Tormey C, Lee E. Liquid plasma versus thawed plasma: Tracking coagulation factor activity changes during storage. Vox Sanguinis 2026 PMID: 41871962, DOI: 10.1111/vox.70248.

  Peer-Reviewed Original Research

  Concepts

• The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

  Cecchini M, Han S, Lee S, Lee K, Kopetz S, Mizrahi J, Hong Y, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Khemka V, Wainberg Z. The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research 2026 PMID: 41870279, DOI: 10.1158/1078-0432.ccr-25-3727.

  Peer-Reviewed Original Research

  This study investigates etrumadenant-based therapy for advanced colorectal cancer, showing improved survival over regorafenib with manageable side effects, supporting further research in refractory cases.

  Full Summary